Coramaze Revenue and Competitors

Petach Tikva,

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Coramaze's estimated annual revenue is currently $4M per year.(i)
  • Coramaze's estimated revenue per employee is $251,000

Employee Data

  • Coramaze has 16 Employees.(i)
  • Coramaze grew their employee count by -6% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M40-18%$10MN/A
#2
$24.8M9929%N/AN/A
#3
$84.1M0N/A$1.2MN/A
#4
$35.6M14230%N/AN/A
#5
$57.5M2296%N/AN/A
#6
$52.7M16825%$129.6MN/A
#7
$21.1M84-3%N/AN/A
#8
$61.2M244-13%N/AN/A
#9
$60.6M19320%$115.5MN/A
#10
$56.2M179-3%$122.9MN/A
Add Company

What Is Coramaze?

Coramaze Technologies was founded in 2013 as a spin off from a research project at the University of Essen. An efficient and safe transcatheter valve repair approach is considered "the next hot thing in cardiovascular med tech". Coramaze Technologies is targeting this space by developing its break-through Tripair® valve repair system for transcatheter implantation into the beating heart of inoperable patients with severe valve regurgitation. Against the background of very promising preclinical safety and demonstrated efficacy in predicate devices, there are many reasons why the Tripair ® valve repair system bears the potential to become the standard of care in the near future.

keywords:N/A

N/A

Total Funding

16

Number of Employees

$4M

Revenue (est)

-6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Coramaze News

2022-04-20 - BioWorld MedTech Patent Highlights: Week 15

The patenting would appear to describe Coramaze Technologies' Tripair™ device for repairing functional tricuspid regurgitation in heart...

2022-04-17 - Transcatheter Mitral Valve Replacement Market Size And ...

KG, Micro Interventional Devices, Colibri Heart Valve, Llc., Neochord Inc., Coramaze Technologies Gmbh. The report provides a good overview...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.4M16-6%N/A
#2
$2.5M2229%N/A
#3
$2.6M2644%N/A
#4
$4.4M320%N/A
#5
N/A3332%N/A